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Summary Forty fixed tissue sections from patients with small cell lung carcinoma (SCCL) have been stained
with a panel of 10 monoclonal antibodies using a peroxidase anti-peroxidase method and the incidence of
staining has been compared to patient characteristics at presentation and to survival. An inverse association
between HMFG2 staining and survival was found with median survival in HMFG2 negative patients 13
months compared to 8 months for HMFG2 positive patients. No such association was found with the other
antibodies and no association was found between staining and disease extent or primary versus secondary
deposits with this panel of antibodies. Epidermal growth factor receptor was detected in 3/38 presentation
biopsies and in these 3 patients mean survival was only 5 months. Further prospective study of HMFG2 as a
prognostic indicator in SCCL is suggested.
Small cell carcinoma of the lung (SCCL) remains a highly
lethal disease, despite the advent of modern chemotherapy,
with overall long-term disease-free survival expected in only
(10%) (Aisner et al., 1983). For patients who have little
chance of long-term survival the goal of therapy is palliation
of symptoms, whilst for the minority who have a better
prognosis, intensive therapy may be indicated in order to
achieve long-term control.
Using current clinical and biochemical evaluation it is
possible to obtain only a crude determinant of prognosis.
Recently studies of cell lines derived from human SCCL
have provided data giving insights into the biochemical,
morphological and genetic diversity of this cancer. One
result of these studies has been the development of
monoclonal antibodies to examine cell surface antigens
associated with SCCL. In terms of prognostic value the
minimum benefit would be to improve the current
unsatisfactory techniques which give information about the
extent of disease. Potentially the linking of clinical events to
cellular behaviour could give an insight to the ways in which
in vitro technology should be further developed to improve
the clinical outcome of this highly malignant cancer. In this
initial study we have examined the cell surface antigen
expression in a series of 40 tissue sections from patients with
SCCL in whom clinical information was available. The aim
was to identify antigen expression which might be related to
response to treatment or prognosis.
Materials and methods
Tissue
Forty paraffin-embedded blocks fixed in 10% buffered
formalin and representing 33 primary bronchial biopsies and
7 metastatic deposits (2 liver, 2 skin, 3 lymph nodes) of
human SCCL were cut as 5gm sections. Full clinical details
were available on 31 primary bronchial biopsies. These 40
samples were obtained from a potential series of 140
patients. Many patients were diagnosed by needle aspirate
and tissue blocks were often too inadequate for sectioning
further.
Antibodies
The MoAbs HMFGI, HMFG2 and CAM 5.2 were used as
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undiluted supernatants. Anti-Leu 7, B5, bombesin, F4, Mo2,
534F8 and the mycl-6E10 antibody for p62c-myc were used
at optimal dilutions. Table I lists the antigenic determinants
of the specific antibodies.
Immunohistochemistry
The 5,pm sections were dewaxed and rehydrated.
Endogenous peroxidase activity was blocked with freshly
prepared 0.3% hydrogen peroxide in methanol for 30min
and the slides then washed in tris buffered saline (pH7.4).
Antigen recognition was enhanced by trypsinisation (0.1%
Sigma crude trypsin in 0.01% EDTA) prior to incubation
with MoAbs. Thereafter a standard 3 step PAP (peroxidase
anti-peroxidase) technique was applied (Sternberger, 1979)
and background staining was reduced by the use of sheep
serum (1:5 dilution). The peroxidase end product was
developed using diaminobenzidine tetrahydrochloride/H202
followed by haematoxylin counter staining.
Assessment
Sections were scored as positive if 10% or more of the cells
stained. Two observers assessed the slides independently. A
Mann-Whitney test was applied to the survival data in the
HMFG2 groups.
Patients
The study groups comprised patients with histologically
confirmed SCLC in whom the extent of disease, treatment
details and response to therapy and survival were known.
All patients received combination chemotherapy as primary
therapy except one patient who had a surgical resection of
a T2 N2 Mo lesion. The chemotherapy consisted of a
combination of (a) methotrexate (200mgm 2) by 24h
infusion with folinic acid rescue, cyclophosphamide (1 gm-2)
and CCNU (100mg-2) in 2 patients; (b) methotrexate
(200mgm-2) by 24h infusion with folinic acid rescue, cyclo-
phosphamide (1 gm-2) and etoposide (120 mgm-2 days 1-3)
in 15 patients; (c) vindesine (3mgm 2) and etoposide
(120mgm-2, days 1-3) in 13 patients. In addition one
patient in group (b) received high dose melphalan
140 mgm-2 with autologous marrow rescue as late
intensification therapy and 3 patients in group (b) received
radical radiotherapy (45Gy in 20 fractions over 4 weeks) to
the primary site and mediastinum, including the patients
receiving melphalan. Regimens (a) and (b) were considered
as intensive chemotherapy for SCCL (Cornbleet et al., 1984)
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Table I Monoclonal antibodies.
Antibody Tissue cell localisation Reference
HMFG1 human milk fat globulin Burchell et al. (1983)
HMFG2 antigens (expressed on Burchell et al. (1984)
epithelial cells)
534F8 neuroectoderm (expressed Cuttitta et al. (1981)
on small cell lung cancer)
x Bombesin neuropeptide Cuttitta et al. (1985)
CAM 5.2 low mol. wt cytokeratins Makin et al. (1984)
B5 surface antigens on Freedman et al. (1985)
activated B cells
Mo2 surface antigens on Todd et al. (1981)
monocytes
Leu-7 surface antigens on natural Cole et al. (1985)
killer cells/neuroectoderm
Mycl-6E10 c-myc oncogene product Sikora et al. (1985)
EGF-RF4 cytoplasmic portion of Gullick et al. (1986)
epidermal growth factor
receptor
whereas regimen (c) was a trial of palliative chemotherapy in
elderly patients in poor health (Allan et al., 1984).
Results
The staining patterns of the 31 primary bronchial biopsies in
31 patients were HMFG1 positive 10/15 tested, HMFG2
17/31, B5 27/29 (2 samples lost in processing), 534F8, 15/31
and F4, 2/31. In addition Mo2 showed positive staining in
5/18 samples tested, Leu-7 in only 3/28 and neither a
bombesin (0/18) nor mycl-6E10 (0/22) stained positively.
Table II records the percentage staining patterns observed.
The pattern of staining observed using this panel of
MoAbs was in no way predictive of limited versus extensive
disease at presentation (criteria for limited/extensive as per
the Veterans Administration Lung Cancer Study Group
(Osterling et al., 1983) nor was it predictive of response to
treatment (only 19% of these patients failed to achieve an
objective response in whom the median survival was 4
months). Expression of antigen was compared with median
survival, irrespective of treatment, and an inverse relation-
ship was found between HMFG2 positivity and survival.
Median survival in those with positive staining was 8 months
(mean 8.1 months) compared with 12.5 months (mean 15.2
months) in those not expressing the antigen. This result is
significant at P<0.05 (Mann-Whitney). No other antibody
demonstrated such a difference as can be seen in Table III.
Of the patients who stained positively for HMFG2 none is
alive, and of those who stained negatively 4 are still alive at
7, 14, 22 and 56 months. As regards intensity of therapy
between these groups they are very evenly balanced with
9/17 HMFG2+ve and 8/13 HMFG2-ve receiving intensive
chemotherapy.
Table II Results of staining 31 primary bronchial biopsies.
Range ofpositivity
Antibody No. positive (0) (% cells stained)
HMFGI 10/15 (67) 10-90
HMFG2 17/31 (55) 10-100
534F8 15/31 (48) 10-75
a Bombesin 0/18 (0)
CAM 5.2 15/30 (50) 10-100
B5 27/29 (93) 20-90
Mo2 5/18 (28) 10-50
Leu 7 3/28 (11) 10-80
Mycl-6E10 0/22 (0) -
EFG-RF4 2/31 (6) 5- 10
Table III Relationship between antibody staining and
survival.
Median survival (months)
Antibody No. positive stain No. negative stain
HMFG2 17 (lA)a 8 months 14 (4A) 13 months
CAM 5.2 15 (3A) 10 months 15 (1A) 8 months
534F8 15 (3A) 10 months 16 (2A) 9 months
B5 27 (SA) 9 months 2 7 months
aA=n patients still alive.
Biopsies were available from 7 metastatic sites - 2 liver, 3
lymph node and 2 skin nodules. A heterogenous staining
pattern similar to the primary tumours was observed with
the panel of antibodies in these metastases, although one
lymph node and one skin nodule showed moderately strong
staining with F4. The patient with the lymph node had
originally been negative for F4 in bronchus and skin nodule
before chemotherapy but developed further disease 10
months later and died at 14 months. The patient with the
skin nodule died of extensive disease at 1 month following
commencement of chemotherapy. The two patients who
demonstrated F4 staining in their primary lung biopsies died
at 6 and 8 months respectively. One patient who had
bronchial biopsies performed before and after intensive
chemotherapy (regimen b), including radical radiotherapy,
showed microscopic residual disease. The initial tumour
stained positively with B5 and 534F8 whereas the residual
tumour post chemotherapy stained additionally with CAM
5.2 and HMFG2.
Discussion
Despite modern intensive chemotherapeutic and radiothera-
peutic intervention, long-term survival in SCCL is limited to
10% of those developing the disease. Although these
survivors will usually have limited disease at presentation
this by no means guarantees long-term survival and although
some helpful prognostic factors have been identified
(Souhami et al., 1985) further useful prognostic markers
would be welcome. The identification of a poorer prognosis
associated with the expression of the epithelial antigen
identified by HMFG2 is thus of interest. Although the
numbers in this retrospective study are small, and we cannot
rule out a chance statistical finding, the result is significant
and four of the HMFG2 negative patients are still alive as
compared with none who were HMFG2 positive. Treatment
given to these groups is very evenly balanced with no
obvious bias towards more intensive therapy. Thus of those
positive for HMFG2, 53% had intensive treatment
compared with 57% of those who were negative. When the
two groups are analysed for clinical disease extent, one of
the major prognostic factors in SCCL, then of those positive
for HMFG2 88% had limited disease as opposed to only
64% of those who were negative. Therefore despite
somewhat more extensive disease present amongst the
HMFG2 negative group the lack of HMFG2 staining
predicted a better prognosis. The significance of HMFG2
positivity following treatment in the patient who had
previously been HMFG2 negative is uncertain but may have
represented the emergence of a new cell clone.
The epithelial glycoprotein identified by HMFG2
(Burchell et al., 1983) is well preserved in formalin but some
measure of denaturing cannot be excluded. In fresh tumour
biopsy samples of SCCL using this MoAb we have a
positivity rate approaching 93% although this includes faint
and patchy staining. Thus formalin fixation may
quantitatively denature the HMFG2 antigen and we feel that
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regard to clinical outcome is indicated. In particular there is
the potential now for the prospective study of HMFG2 in
serum in SCCL in relation to clinical outcome and disease
detection. HMFG2 will detect other carcinomas such as
breast (Burchell et al., 1984) and labelling of HMFG2 with
1231 has been used to localise ovarian tumours effectively
(Epenetos et al., 1982). The absence of HMFG1 staining in
breast carcinoma has been shown to predict poor survival
(Wilkinson et al., 1984), but another study (Berry et al.,
1985) could not demonstrate prognostic significance of
HMFG1 or HMFG2 staining in the same cancer. With
regard to the differential diagnosis of SCCL an effective
panel of antibodies may be emerging (Hay et al., 1986).
Distinction from lymphoma is now possible but further
studies on staining patterns of non-small cell lung cancer are
required. The cytokeratin antibody anti CAM 5.2 identifies a
low molecular weight cytokeratin restricted to simple
epithelia and was positive in 50% of our cases but without
prognostic significance. This, together with the HMFGI and
HMFG2 antigens, supports the notion of an epithelial origin
for SCCL. Smaller numbers were studied using HMFG1
compared with HMFG2 as the latter has been found to be
more strongly expressed on tumour glycoproteins (Burchell
et al., 1983). However HMFG1 showed a similar staining
pattern to HMFG2.
The neuroendocrine MoAb 534F8 showed moderately
strong staining in 48% of biopsies but without obvious
prognostic significance. The anti-bombesin MoAb did not
appear to react with fixed tissue in this study although in
fresh tissues 13/17 stained positively. The lymphoid-
associated MoAbs were of interest with the monocyte
marker Mo2 positive in 28% of samples and the B-cell-
restricted activation antigen, B5, (Freedman et al., 1985) very
strongly expressed in 93% of samples. The NK
cell/neuroendocrine MoAb anti-Leu 7 was positive in only
11% of these fixed tissues compared with 86% when used in
fresh SCCL (unpublished data). Expression of p62c-myc was
not seen in 22 tested samples.
F4, the internal portion of the epidermal growth factor
(EGF) receptor (Gullick et al., 1986), was expressed
infrequently in the primary biopsies 2/31 but perhaps
significantly was expressed in 2/7 metastatic sites. In the case
of one of the latter F4 was not expressed in the primary site
or in a skin nodule prior to chemotherapy. At relapse 10
months later the metastatic lymph node expressed F4 and
this patient died 4 months later. The mean survival of the 3
patients in whom F4 was expressed at diagnosis was 5
months. In none of these sections was staining strong or
homogeneous. Cerny et al. (1986) examined 15 cases of
SCCL for epidermal growth factor receptor and could not
demonstrate its expression, in contrast to non-small cell lung
cancer. However, they did comment that foci of faintly
positive cells could be seen. Thus it seems that EGF
receptors are rarely found in SCCL. The presence of EGF
receptors in human breast cancer has been associated
positively with metastatic disease and negatively with
oestrogen receptor status (Sainsbury et al., 1985), and EGF
receptors were more likely to be present in invasive
transitional cell carcinoma of bladder than in superficial
bladder tumours (Neal et al., 1985). These findings would
suggest that some epithelial tumours positive for EGF
receptors are likely to have a poor prognosis and further
studies with SCCL may confirm that for this disease.
In conclusion, an increasing panel of MoAbs is available
for characterising SCCL. Some of these will be of value in
differential diagnosis. This study indicates that the presence
of HMFG2 on human SCCL may represent a poor
prognostic sign and requires prospective evaluation. In
addition expression of the EGF receptor may indicate a
particularly unfavourable prognosis.
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